from seed
to summit.

We fuel the ascent of biotech pioneers.

Investing in computationally-enabled therapeutic platforms from development candidate through first-in-human.

Teams We're Backing

Fauna Bio is harnessing 100 million years of evolution to cure human disease. Using its proprietary Convergence™ AI platform, the company analyzes genomic data from animals that have naturally evolved to resist specific illnesses. By identifying and replicating these disease-resistant mechanisms, Fauna Bio discovers novel drugs for humans, with its lead asset targeting heart disease associated with Pulmonary Hypertension.

Read more here.

Modulate Bio's AI-powered discovery platform is engineered to overcome the limitations of current neurological treatments. By precisely designing novel GABAA positive allosteric modulators, the company is developing a pipeline of differentiated therapies for Essential Tremor, epilepsy, and anxiety that promise greater efficacy without the common side effects of today's standards of care.

Read more here.

.

Screenshot 2026-03-02 at 10.50.32 AM.png

Coding Bio's AI-powered discovery platform is engineered to overcome the limitations of current immunotherapies. By optimizing for functionality instead of binding affinity, the company is developing a pipeline of differentiated cancer therapies—such as treatments for multiple myeloma—that promise better dosing capabilities and greater efficacy without minimized systemic toxicity of today's standards of care.

Read more here.

Fauna Bio is harnessing 100 million years of evolution to cure human disease. Using its proprietary Convergence™ AI platform, the company analyzes genomic data from animals that have naturally evolved to resist specific illnesses. By identifying and replicating these disease-resistant mechanisms, Fauna Bio discovers novel drugs for humans, with its lead asset targeting heart disease associated with Pulmonary Hypertension.

Read more here.

Screenshot 2026-04-16 at 3.27_edited.png

Novoron Bioscience is pioneering a proactive approach to treating brain diseases by protecting the vital communication links between brain cells before damage occurs. By engineering a new class of therapies that act as a molecular firewall, the company quarantines toxic proteins to break the transmission chain of cognitive decline and preserve healthy neurons.

Read more here.

Avery Therapeutics is pioneering a regenerative approach for treating heart failure by developing tissue-engineered therapeutics that repair damaged cardiac muscle. By advancing an off-the-shelf biologic heart graft, the company seeks to achieve targeted tissue repair, actively regrowing heart muscle and blood vessels, and ultimately restoring vital cardiac function.

Read more here.